Infinity Pharmaceuticals Inc. (NASDAQ:INFI) President Lawrence E. Bloch bought 500,000 shares of the company’s stock in a transaction on Wednesday, December 6th. The stock was purchased at an average price of $1.81 per share, with a total value of $905,000.00. Following the completion of the transaction, the president now directly owns 580,944 shares of the company’s stock, valued at approximately $1,051,508.64. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Infinity Pharmaceuticals Inc. (NASDAQ INFI) traded down $0.09 during mid-day trading on Thursday, hitting $1.71. The stock had a trading volume of 5,042,700 shares, compared to its average volume of 1,347,128. Infinity Pharmaceuticals Inc. has a 12 month low of $0.93 and a 12 month high of $3.84.

Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.06. The company had revenue of $6.00 million during the quarter, compared to analyst estimates of $14.70 million. During the same period in the previous year, the company posted ($0.39) EPS. sell-side analysts expect that Infinity Pharmaceuticals Inc. will post -0.93 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Infinity Pharmaceuticals by 27.7% in the first quarter. Vanguard Group Inc. now owns 4,701,769 shares of the biotechnology company’s stock valued at $15,187,000 after buying an additional 1,021,128 shares during the period. Platinum Investment Management Ltd. increased its stake in shares of Infinity Pharmaceuticals by 74.3% in the third quarter. Platinum Investment Management Ltd. now owns 1,411,832 shares of the biotechnology company’s stock valued at $1,877,000 after buying an additional 601,600 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Infinity Pharmaceuticals by 32.7% in the second quarter. Dimensional Fund Advisors LP now owns 652,481 shares of the biotechnology company’s stock valued at $1,024,000 after buying an additional 160,814 shares during the period. Legal & General Group Plc increased its stake in shares of Infinity Pharmaceuticals by 2,430.0% in the second quarter. Legal & General Group Plc now owns 349,346 shares of the biotechnology company’s stock valued at $548,000 after buying an additional 335,538 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Infinity Pharmaceuticals by 4.5% in the first quarter. Geode Capital Management LLC now owns 345,366 shares of the biotechnology company’s stock valued at $1,114,000 after buying an additional 15,005 shares during the period. 54.41% of the stock is owned by institutional investors.

Several equities analysts have commented on the company. ValuEngine upgraded Infinity Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, October 12th. Zacks Investment Research upgraded Infinity Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 17th. Finally, Wells Fargo & Company upgraded Infinity Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Thursday, October 12th.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/07/infinity-pharmaceuticals-inc-infi-president-lawrence-e-bloch-acquires-500000-shares.html.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.

Insider Buying and Selling by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.